The Andelyn Difference


“What’s in a name?” the saying goes. In this case, much more than meets the eye. Andelyn Biosciences is much more than a corporate name for a biotech business. For this innovative biotech organization, the patient always comes first. Inspired by two young gene therapy pioneers Andelyn Biosciences is a combination of the names of the children who participated in the momentous Phase I clinical trials at Nationwide Children’s Hospital.

In 2006, eight-year-old Andrew Kilbarger underwent the U.S.’s first-in-human investigational gene therapy for Duchenne muscular dystrophy. Later in 2015, at only eight weeks old, infant Evelyn Villarreal received experimental gene therapy for spinal muscular atrophy. With its hybrid name, the organization seeks to honor those who participated in trailblazing research and have made gene therapies feasible for patients today.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene